COVID-19 Collection

Journal article

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

Abstract:: Background
Previous infection with SARS-CoV-2 affects the immune response to the first dose of the SARS-CoV-2 vaccine. We aimed to compare SARS-CoV-2-specific T-cell and antibody responses in health-care workers with and without previous SARS-CoV-2 infection following a single dose of the BNT162b2 (tozinameran; Pfizer–BioNTech) mRNA vaccine.
Methods
We sampled health-care workers enrolled in the PITCH study across four hospital sites in t... Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Angyal, A., Longet, S., Moore, S. C., Payne, R. P., Harding, A., Tipton, T., Rongkard, P., Ali, M., Hering, L. M., Meardon, N., Austin, J., Brown, R., Skelly, D., Gillson, N., Dobson, S. L., Cross, A., Sandhar, G., Kilby, J. A., Tyerman, J. K., … de Silva, T. I. (2021). T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet Microbe, 3(1), E21–E31.

MLA Style

Angyal, A, et al. “T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously Infected and SARS-CoV-2-Naive UK Health-Care Workers: a Multicentre Prospective Cohort Study.” Lancet Microbe, vol. 3, no. 1, 2021, pp. E21–E31.

Chicago Style

Angyal, A, S Longet, SC Moore, et al. 2021. “T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously Infected and SARS-CoV-2-Naive UK Health-Care Workers: a Multicentre Prospective Cohort Study.” Lancet Microbe 3 (1): E21–E31.
Print

Access Document

Files:: Angyal_et_al_2021_Tcell_and_antibody.pdf

(Preview, Version of record, pdf, 957.1KB, Terms of use)

Publisher copy:: 10.1016/S2666-5247(21)00275-5

Authors

+ Angyal, A More by this author

Role:: Author

+ Longet, S More by this author

Role:: Author

+ Moore, SC More by this author

Role:: Author

+ Payne, RP More by this author

Role:: Author

+ Harding, A More by this author

Role:: Author

More authors...

Contributors

+ PITCH Consortium Group

Role:: Contributor

+ Wellcome Trust More from this funder

Publisher:: Elsevier
Journal:: Lancet Microbe More from this journal
Volume:: 3
Issue:: 1
Pages:: E21-E31
Publication date:: 2021-11-09
DOI:: 10.1016/S2666-5247(21)00275-5
EISSN:: 2666-5247

Language:: English
Keywords:: FFR
Pubs id:: 1185655
Local pid:: pubs:1185655
Deposit date:: 2021-11-11
ARK identifier:: ark:/29072/ora_c01eeedd794243a8b69ce7b8577ea00d

Terms of use

Copyright holder:: Angyal et al.
Copyright date:: 2021
Rights statement:: © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP